Merus appoints Mark Iwicki as President of the Supervisory Board

June 01, 2015

Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of its Supervisory Board.

“We welcome Mark as an instrumental addition to our Supervisory Board,” said Ton Logtenberg, Merus’ CEO. “Mark is a senior healthcare executive with a diverse and extensive background in commercialization, R&D and general management with a proven track record in creating shareholder value. His corporate leadership experience makes him an ideal fit for Merus and his contribution will be vital as the company works to successfully advance its oncology drug pipeline into the clinic.”

Mr. Iwicki most recently served as President and Chief Executive Officer of biotechnology company Civitas Therapeutics until it was acquired by Acorda Therapeutics in 2014. Previously, Mr. Iwicki was the CEO of Blend Therapeutics and Sunovion Pharmaceuticals.

“I am pleased to join Merus at such a significant moment in the company's development and look forward to working alongside a world-class team with exceptional leadership in therapeutic antibodies,” said Mark Iwicki. “It is an honor to be able to share my experience and contribute to the future direction and growth of a company working so diligently to develop differentiating products to prolong and improve the lives of cancer patients.”

Mark will replace Gerard van Odijk who has been the company’s President of the Board for the last 7 years. “I would like to thank Gerard for his many valuable contributions to building Merus from a preclinical into a clinical-stage company. I wish him success in his many endeavors in the biopharmaceutical industry,” said Ton Logtenberg.

###

About Merus B.V.
Merus is a Dutch biotechnology company developing cancer therapeutics based on human bispecific antibodies. Merus’ bispecific antibodies have the robust and proven full-length IgG format, they are manufactured using industry standard processes and have predictable in vivo behavior such as long half-life and low immunogenicity. Merus has two lead programs in development, MCLA-128 for the treatment of HER2 expressing solid tumors, and MCLA-117 for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company is also developing a broad pipeline of preclinical programs in immuno-oncology using its unique technology platforms. Please visit www.merus.nl.